top of page

NCI-2017-02047

MA.39 Tailor RT A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer


This is a research study to see if some women with breast cancer can skip a type of radiation treatment (regional radiotherapy) without affecting their chances of recovery. The goal is to avoid unnecessary side effects from radiation treatment for some women who may not need it. Women with Early-stage breast cancer that has spread to nearby lymph nodes (low-risk) and have Hormone receptor-positive (ER+) breast cancer, HER2-negative (HER2-) are eligible to participate in this study.


HER-2 negative: It is a type of breast cancer where cancer cells have normal levels of the protein called HER-2. Cancer cells that are HER-2 negative grow more slowly and are less likely come back or spread to other parts of the body than cancers that have too much HER-2.

Hormone Receptor positive: It is a type of breast cancer where the cancer cells have receptors on their surface that can attach to hormones in the body, particularly estrogen and/or progesterone. When these receptors attach to hormones, they can stimulate the cancer cells to grow.

Regional radiotherapy: Radiotherapy to the whole breast/chest area and the surrounding lymph glands is called regional radiotherapy.


For more information about the trial, click the link below:

NCI-2022-08654

Clinical Trial Site: Einstein/Columbia


To see all available clinical trials click here. 



Recent Posts

See All

NCI-2019-07694

Phase II Study of Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Previously Treated Advanced Biliary Tract Cancer (NAPOLI-2) This is a research study called NAPOLI-2. It is designed to see

NCT05908786

A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED PLATFORM STUDY EVALUATING THE EFFICACY AND SAFETY OF NEOADJUVANT IMMUNOTHERAPY COMBINATIONS IN PATIENTS WITH SURGICALLY RESECTABLE HEPATOCELLULAR CAR

NCT05904886

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatoce

Comentários


bottom of page